首页 › 慢性淋巴细胞白血病 › 明尼苏达州 › Rochester
Rochester MN 慢性淋巴细胞白血病临床试验
19项针对 慢性淋巴细胞白血病的研究正在 Rochester及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中2 期
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
招募中1/2 期
- Research Site, Rochester
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Mayo Clinic Rochester, Rochester
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Mayo Clinic Rochester, Rochester
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
招募中3 期
- Mayo Clinic Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Mayo Clinic Rochester, Rochester
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
招募中1 期
- Mayo Clinic Rochester, Rochester
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Mayo Clinic, Rochester
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- Mayo Clinic, Clinical Trials Referral Office, Rochester
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
招募中2 期
- Mayo Clinic, Rochester
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
招募中1 期
- Mayo Clinic in Rochester, Rochester
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
招募中欢迎健康志愿者
- Mayo Clinic in Rochester, Rochester
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
招募中观察性研究欢迎健康志愿者
- Mayo Clinic in Rochester, Rochester
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中2 期
- Mayo Clinic in Rochester, Rochester
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Mayo Clinic- Minnesota, Rochester
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Mayo Clinic- Minnesota, Rochester
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
招募中观察性研究
- Mayo Clinic in Rochester, Rochester
Family Study of Lymphoproliferative Disorders
招募中观察性研究欢迎健康志愿者
- Mayo Clinic, Rochester
Q702 for the Treatment of Patients With Hematologic Malignancies
招募中1 期
- Mayo Clinic in Rochester, Rochester
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Columbus, OH28 项研究
- Durham, NC27 项研究
- Washington, DC22 项研究
- Seattle, WA20 项研究
- New York City, NY18 项研究
- Houston, TX17 项研究
- Baldwin Park, CA16 项研究
- Milwaukee, WI15 项研究
- Chicago, IL14 项研究
- Cincinnati, OH14 项研究
- Nashville, TN13 项研究
Rochester的其他研究
- 乳腺癌42 项研究
- 非小细胞肺癌37 项研究
- 转移性癌症31 项研究
- 癌症（所有类型）30 项研究
- 结直肠癌29 项研究
- 卵巢癌29 项研究
- 多发性骨髓瘤24 项研究
- 前列腺癌22 项研究
- 心力衰竭22 项研究
- 胰腺癌22 项研究
- 肺癌20 项研究
- 子宫内膜癌20 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。